MARSHBANKS TRACY 4
4 · ANI PHARMACEUTICALS INC · Filed May 11, 2018
Insider Transaction Report
Form 4
MARSHBANKS TRACY
Director
Transactions
- Sale
Common Stock
2018-05-09$62.05/sh−20,517$1,273,080→ 430,084 total(indirect: See Footnote) - Sale
Common Stock
2018-05-10$62.14/sh−17,685$1,098,946→ 412,399 total(indirect: See Footnote) - Sale
Common Stock
2018-05-10$62.03/sh−24,229$1,502,925→ 388,170 total(indirect: See Footnote)
Footnotes (4)
- [F1]This transaction was executed in multiple trades at prices ranging from $62.00 to $62.335. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F2]This transaction was executed in multiple trades at prices ranging from $62.00 to $62.5425. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $62.00 to $62.11. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F4]Held by FA Private Equity Fund IV, L.P., FA Private Equity Fund IV GmbH & Co. Beteiligungs KG, The Productivity Fund IV Liquidating Trust, and The Productivity Fund IV Advisors Fund Liquidating Trust, which the Reporting Person may be deemed to be a beneficial owner pursuant to rule 16a-1(a)(1).